The word stones travels badly. Someone on a GLP-1 who hears that these medicines are associated with stones has almost certainly been hearing about the gallbladder, because cholelithiasis, gallstones, appears on every label in the class, repeatedly, with a warning section of its own. Kidney stones are a different subject in a different organ, and the label record for them is much thinner: exactly one product in the class mentions them. This page reports that entry, sizes it honestly, and keeps the two kinds of stones apart, because blurring them is the mistake readers most easily make.
The site has covered the gallbladder side at Gallbladder Symptoms on a GLP-1: What to Watch For and the kidney context more broadly at GLP-1s and Your Kidneys: Why Dehydration Is the Risk. Kidney stones themselves have gone unmentioned until now, and the honest version of the story is short enough to tell in full.
Urolithiasis, in plain language
Urolithiasis is the clinical term for stones forming anywhere in the urinary tract, which includes the kidneys and everything downstream of them. When the Wegovy label uses the word, it is referring to that whole category, of which kidney stones are the best known member. The term is precise in a way everyday language is not, and precision helps here, because it keeps the subject anchored to the urinary tract and away from the gallbladder, where a different kind of stone forms by a different mechanism under a different label status.
Defining the word is also most of what can be done with it. A label entry names an event that was recorded in a trial; it does not explain the biology behind it, and neither, responsibly, will this article.
What the Wegovy label reports
The adverse reactions section of the Wegovy label carries a urolithiasis entry, and it is specific. In a cardiovascular outcomes trial, 1.2 percent of Wegovy-treated patients and 0.8 percent of patients receiving placebo reported urolithiasis, including serious reactions that were reported more frequently among patients receiving Wegovy, 0.6 percent, than placebo, 0.4 percent.
Those figures deserve honest sizing from both directions. More events were reported on the medicine than on placebo, including more serious ones, and that is what the entry says. At the same time, a difference of 1.2 against 0.8 percent is small in absolute terms, it comes from one trial, and it belongs to one product. Neither reading cancels the other, and an article that dramatised the gap or explained it away would be doing the same thing in opposite directions. The numbers are the numbers; they are modest; they exist.
GLP 1 Tracker AppWater, side effects and doses logged day by day, privately on your phone. If a urinary symptom ever needs discussing, a dated record beats memory.
Get the app
What the other labels say
Here the record goes quiet. The current Ozempic, Zepbound, Mounjaro and Saxenda labels contain no urolithiasis entry and no mention of kidney stones at all. That silence needs the same careful reading this site gives every empty label section: a label carries what was studied and submitted for that product, so an absence is a statement about trials and filings, not a demonstrated difference between molecules. Reading the labels as a ranking, with Wegovy as the stone drug and the others as clean, mistakes paperwork for pharmacology.
So the full picture is this: one product carries a urolithiasis entry with small absolute numbers from one trial, and the rest of the class says nothing. That is the entire label record on kidney stones, and everything beyond it, causes, mechanisms, comparisons between medicines, is not something any label supports and not something this article will invent.
Not the same stones as the gallbladder
It is worth being blunt about the contrast, because it organises everything above. Cholelithiasis appears on every label in the class, repeatedly, with its own warning section; urolithiasis appears once. Gallstones form in the gallbladder from bile chemistry, often in the context of rapid weight loss, which is why the class pays them so much attention. Kidney stones form in the urinary tract from a different set of circumstances entirely. Different organs, different mechanisms, different label status.
A reader who has heard stones and GLP-1 in the same sentence was, with high likelihood, hearing about the gallbladder, and the page to read is Gallbladder Symptoms on a GLP-1: What to Watch For. This page exists so that the rarer, thinner kidney stone record also has a home, clearly labelled as such.
Where fluids fit, and where they do not
Every label in the class warns about acute kidney injury due to volume depletion from gastrointestinal losses, the nausea, vomiting and diarrhea that can accompany these medicines. That warning is about the kidneys' blood supply, not about stones, and no label in the class connects fluid intake to stone formation on these medicines. Fluids nevertheless come up in almost every conversation about the urinary tract, which is why this article touches them at all, and the site's pages on hydration and electrolytes cover the practical side.
What this article will not do is turn that adjacency into advice. Drinking enough is worth doing for reasons the labels themselves state, and the broader kidney context is laid out at GLP-1s and Your Kidneys: Why Dehydration Is the Risk. But no fluid target is a stone measure, no label says dehydration causes stones on these medicines, and an article reporting a label entry should not quietly become an article proposing a mechanism.
Symptoms that belong with a clinician
One routing, stated once: severe pain in the side or back, pain on passing urine, or blood in the urine belongs with a clinician promptly. That holds whatever medicine a person is taking, and working out what is going on is a job for someone who can examine and test, not for an article or for the reader guessing at themselves. This page reports what one label says about trial populations; it does not describe how to self-diagnose, and it deliberately does not run through every possible symptom.
That is the whole story the labels have to tell. One entry, one product, small numbers, one trial, and silence everywhere else, with the gallbladder carrying the class's real attention on stones. Anyone with a question in this neighborhood brings it to a prescriber, who has the label and the person's history in front of them, which is more than any article will ever have.
Frequently asked questions
Can GLP-1 medicines cause kidney stones?
One label in the class reports them. The Wegovy adverse reactions section carries a urolithiasis entry stating that in a cardiovascular outcomes trial, 1.2 percent of Wegovy-treated patients and 0.8 percent of placebo patients reported urolithiasis, with serious reactions reported more frequently on Wegovy, 0.6 percent against 0.4 percent. That is one trial, one product and a small absolute difference, and it is a statement about trial populations rather than about any individual reader.
Do Ozempic, Zepbound, Mounjaro or Saxenda list kidney stones?
No. The current labels for those products carry no urolithiasis entry and no mention of kidney stones at all. An absence on a label reflects what was studied and submitted for that product rather than a demonstrated difference between molecules, so the labels cannot be read as a ranking of which medicine is safer for the urinary tract. The entry exists where a trial captured it, and nowhere else.
Are kidney stones the same as the gallstones on the GLP-1 labels?
No, and the distinction matters. Cholelithiasis, gallstones, appears on every label in the class, repeatedly, and has its own warning section, because rapid weight loss is a known context for gallstone formation. Kidney stones form in the urinary tract, an entirely different organ with different mechanisms, and only one label mentions them at all. A reader who has heard the word stones in connection with these medicines has almost certainly been hearing about the gallbladder.
Does dehydration on a GLP-1 cause kidney stones?
No label makes that connection, and this article does not propose one. What every label in the class does warn about is acute kidney injury due to volume depletion from gastrointestinal losses, which is why fluid intake comes up in almost every conversation about the urinary tract on these medicines. Drinking enough is worth doing for reasons the labels state; it is not a stone measure, and this article names no fluid target as one.
What kidney stone symptoms need medical attention on a GLP-1?
Severe pain in the side or back, pain on passing urine, or blood in the urine belongs with a clinician promptly, and that routing holds whether or not the medicine is involved. Self-diagnosis is not the job of an article, and neither is a symptom checklist. This page reports what one label says; working out what any particular symptom is, is a conversation for a clinician who can examine and test.